

Application No.: 10/087,190

Docket No.: 511582003420

CLAIM AMENDMENTS

1-3. (canceled)

4. (currently amended): ~~A composition of claim 1 wherein the substance comprises an~~
An antibody or fragment thereof that specifically binds to a 121P1F1-related protein SEQ ID NO: 2.

5. (currently amended): The antibody or fragment thereof of claim 4, which is
a monoclonal antibody.

6. (currently amended): ~~A recombinant protein comprising an antigen-binding region~~
of a The antibody or fragment thereof of claim 5, wherein the monoclonal antibody of claim 5 is
recombinantly produced.

7. (currently amended): The antibody or fragment thereof of claim 4, which is ~~labeled~~
with a detectable marker conjugated to an agent.

8. (canceled)

9. (currently amended): The antibody or fragment of an antibody thereof of claim 4,
[[which]] wherein the fragment is an Fab, F(ab')₂, Fv or sFv fragment.

10. (currently amended): The antibody or fragment thereof of claim 4, which is a human
antibody, a humanized antibody or a chimeric antibody.

11. (currently amended): A non-human transgenic animal that produces an antibody of
claim 4 or fragment thereof that specifically binds to a protein comprising SEQ ID NO: 2.

12. (currently amended): A hybridoma that produces an antibody ~~of claim 5~~ or fragment
thereof that specifically binds to a protein comprising SEQ ID NO: 2.

Application No.: 10/087,190

Docket No.: 511582003420

13. (currently amended): ~~[[A]] The antibody or fragment thereof of claim 6, wherein the monoclonal antibody is a single chain monoclonal antibody that immunospecifically binds to a 121P1F1-related protein, and that comprises the variable domains of the heavy and light chains of a monoclonal antibody of claim 5~~ protein comprising SEQ ID NO: 2.

14. (canceled)

15. (currently amended): A method of delivering ~~a cytotoxic agent or a diagnostic~~ an agent to a cell that expresses 121P1F1 (SEQ ID NO: 2), said method comprising:
providing the ~~cytotoxic agent or the diagnostic agent~~ conjugated to an antibody or fragment thereof of claim 4; and,
exposing the cell to the antibody-agent or fragment-agent conjugate.

16-18. (canceled)

19. (currently amended): ~~[[The]] An immunogenic composition of claim 1 wherein the substance comprises an analog of a peptide of eight, nine, ten, or eleven contiguous amino acids of Figure 2A, Figure 2B, Figure 2C, Figure 2D, Figure 2E, or Figure 2F (SEQ ID NO: _____)~~ comprising an immunogenic portion of SEQ ID NO: 2.

20. (currently amended): ~~[[A]] The immunogenic composition of claim 1~~ claim 19 wherein the ~~substance~~ immunogenic portion comprises a CTL polypeptide epitope of the amino acid sequence of Figure 2A, Figure 2B, Figure 2C, Figure 2D, Figure 2E, or Figure 2F (SEQ ID NO: _____) NO: 2, with a *proviso* that the epitope is not the entire amino acid sequence of Figure 2A (SEQ ID NO: _____) NO: 2.

21. (currently amended): The immunogenic composition of claim 20 wherein the CTL epitope comprises a polypeptide selected from Tables V-XVIII, XXVI, and XXVII, with a *proviso* that the epitope is not the entire amino acid sequence of Figure 2A (SEQ ID NO: _____) NO: 2.

Application No.: 10/087,190

Docket No.: 511582003420

22-47. (canceled)

48. (currently amended): A method of ~~claim 47~~ of inhibiting growth of cancer cells that express 121P1F1, ~~the method comprising steps of:~~

administering to said cells an antibody or fragment thereof ~~either of which~~ specifically bind to a 121P1F1~~[[related]]~~ protein (SEQ ID NO: 2).

49. (currently amended): ~~[[A]] The method of claim 47 claim 48 of inhibiting growth of cancer cells that express 121P1F1, the method comprising steps of:~~

~~administering to said cells a vector that encodes wherein the antibody or fragment thereof is~~
a single chain monoclonal antibody that immunospecifically binds to ~~[[an]] the~~ 121P1F1~~[[related]]~~ protein.

50-53. (canceled)

54. (currently amended): ~~[[A]] The method of claim 47 claim 48 of inhibiting growth of cancer cells that express 121P1F1 and a particular HLA molecule, the method comprising steps of:~~

administering to said cells human T cells, wherein said T cells specifically recognize an 121P1F1 peptide sequence in the context of the particular HLA molecule.

55-64. (canceled)

65. (currently amended): A method of generating a mammalian immune response directed to 121P1F1 (SEQ ID NO: 2), the method comprising:

exposing cells of the mammal's immune system to an immunogenic portion of

a) ~~an 121P1F1-related protein~~ SEQ ID NO: 2 and/or

b) a nucleotide sequence that encodes said protein,

whereby an immune response is generated to 121P1F1.

Application No.: 10/087,190

Docket No.: 511582003420

66. (currently amended): ~~[[A]] The method of inducing an immune response of claim 65, said method comprising:~~

~~providing a 121P1F1-related protein wherein the immunogenic portion of SEQ ID NO: 2 that comprises at least one T cell or at least one B cell epitope[[;~~

~~contacting the epitope with a mammalian immune system T cell or B cell respectively, whereby the T cell or B cell is induced]].~~

67. (currently amended): The method of claim 66, wherein the immune system cell is a B cell, whereby the induced cell epitope induces a B cell generates antibodies to generate an antibody that specifically binds to the 121P1F1-related protein B cell epitope.

68. (currently amended): The method of claim 66, wherein the immune system cell is a T cell epitope activates ~~[[that is]]~~ a cytotoxic T cell (CTL), whereby the activated CTL kills which is capable of killing an autologous cell that expresses the 121P1F1~~[[related]]~~ protein.

69. (currently amended): The method of claim 66, wherein the immune system cell is a T cell ~~[[that is]]~~ activates a helper T cell (HTL), whereby the activated HTL secretes cytokines that facilitate the cytotoxic activity of a cytotoxic T cell (CTL) or the antibody producing activity of a B cell.

70. (currently amended): An assay for detecting ~~the presence~~ expression levels of a 121P1F1~~[[related protein or polynucleotide]]~~ gene product in a biological sample and a normal sample obtained from a patient who has or who is suspected of having cancer, comprising steps of:

contacting the biological sample with a substance of claim 1 and the normal sample an antibody or fragment thereof that specifically binds to the 121P1F1~~[[related protein or polynucleotide, respectively]]~~ gene product; and~~[[;~~

determining that there is a complex of the substance antibody or fragment thereof and 121P1F1~~[[related protein or the substance and 121P1F1-related polynucleotide, respectively]]~~ gene product.

Application No.: 10/087,190

Docket No.: 511582003420

71-77. (canceled)

78. (new) The antibody or fragment thereof of claim 7, wherein the agent is a diagnostic agent or a cytotoxic agent.

79. (new) The antibody or fragment thereof of claim 78, wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins.

80. (new) The antibody or fragment thereof of claim 79, wherein the radioactive isotope is selected from the group consisting of ^{211}At , ^{131}I , ^{125}I , ^{90}Y , ^{186}Re , ^{188}Re , ^{153}Sm , ^{212}Bi , ^{32}P and radioactive isotopes of Lu.

81. (new) The antibody or fragment thereof of claim 79, wherein the chemotherapeutic agent is selected from the group consisting of taxol, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin.

82. (new) The antibody or fragment thereof of claim 79, wherein the toxin is selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin.